Mustang Bio Inc (MBIO) Stock Price, Quote & News

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.mustangbio.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

Renato17 Aug. 28 at 12:53 PM

$FBIO $FBIOP $DERM $CKPT $MBIO

0 · Reply

Zellchair Aug. 28 at 12:41 PM

$FBIO $FBIOP $DERM $CKPT $MBIO Me (+343,57%) vs FBIO (-2,89%) last 20 months (image), considering that Fortress has been my largest holding several times and for long periods during this time. The curves/development will be more correlated to FBIOP (yes, I continue to prefer the preferred stock) going forward. 9 substack posts about why in link (free) here: https://zellchair.substack.com/

0 · Reply

nonamestockz Aug. 28 at 11:09 AM

$AQB rocket like $MBIO which I predicted too

0 · Reply

FinSUN Aug. 27 at 7:43 PM

$MBIO let's go now

0 · Reply

Guiping Aug. 27 at 6:44 PM

$MBIO best wishes don’t die.

0 · Reply

FinSUN Aug. 22 at 3:59 PM

$MBIO time to start a new position here

0 · Reply

ThatDudeWithNoMoney Aug. 20 at 7:24 PM

$IVF this administration knows they can manipulate the market without repercussions. They’re going to bring up IVF For All after this administration’s dark pool exchanges buy the dip for them. Won’t be long until the Trump administration shines a light on the topic. *This is strictly speculative insight and NOT financial advice* $JAGX $TNXP $MBIO

2 · Reply

SPYmyQQQ Aug. 20 at 6:29 PM

🚨 New Signal ✅ 💊 $MBIO 🗓️ Aug 20, 2025 🎯 Entry: $1.6199 🎯 Target: $1.9151 (+18.22%)

0 · Reply

CallMeEddieMush Aug. 14 at 8:44 PM

$MBIO this was $22 this year?? simple pump and dump or what???

3 · Reply

2pumps1dump Aug. 14 at 8:57 AM

$MBIO a lot of improvements being made. Update sends it. 🚀

0 · Reply

Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 8:30 AM EDT - 2 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mar 5, 2025, 4:15 PM EST - 6 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Feb 27, 2025, 4:05 PM EST - 6 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 11, 2025, 4:10 PM EST - 7 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 7 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 7 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Jan 14, 2025, 8:00 AM EST - 8 months ago

Mustang Bio Announces Reverse Stock Split

Nov 12, 2024, 8:30 AM EST - 10 months ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 7, 2024, 8:30 AM EST - 10 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 11 months ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 1 year ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 1 year ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 1 year ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 2 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 2 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Renato17 Aug. 28 at 12:53 PM

$FBIO $FBIOP $DERM $CKPT $MBIO

0 · Reply

Zellchair Aug. 28 at 12:41 PM

0 · Reply

nonamestockz Aug. 28 at 11:09 AM

$AQB rocket like $MBIO which I predicted too

0 · Reply

FinSUN Aug. 27 at 7:43 PM

$MBIO let's go now

0 · Reply

Guiping Aug. 27 at 6:44 PM

$MBIO best wishes don’t die.

0 · Reply

FinSUN Aug. 22 at 3:59 PM

$MBIO time to start a new position here

0 · Reply

ThatDudeWithNoMoney Aug. 20 at 7:24 PM

2 · Reply

SPYmyQQQ Aug. 20 at 6:29 PM

🚨 New Signal ✅ 💊 $MBIO 🗓️ Aug 20, 2025 🎯 Entry: $1.6199 🎯 Target: $1.9151 (+18.22%)

0 · Reply

CallMeEddieMush Aug. 14 at 8:44 PM

$MBIO this was $22 this year?? simple pump and dump or what???

3 · Reply

2pumps1dump Aug. 14 at 8:57 AM

$MBIO a lot of improvements being made. Update sends it. 🚀

0 · Reply

QuantNut Aug. 13 at 10:44 PM

$MBIO hmmmm… this week or next week? I like this week just cuz I like this week 😉😉😉

0 · Reply

Vinniesb Aug. 13 at 5:57 PM

$MBIO

0 · Reply

QuantNut Aug. 13 at 2:17 PM

$MBIO don’t expect big spikes. Only small steps up😉😉🤑🤑🤑

0 · Reply

warrants_Moon Aug. 13 at 4:37 AM

$CRDF undervalued bios is what you should buying because healthcare has been getting slaughtered $MBIO $TPST $VSTM

1 · Reply

Mg_1970 Aug. 12 at 3:21 PM

$MBIO Uhmm... 🙄🤦‍♂️

0 · Reply

QuantNut Aug. 12 at 2:38 PM

$MBIO see ya at $2 🤑🤑🤑

0 · Reply

2pumps1dump Aug. 12 at 8:39 AM

$MBIO need to be adding, it’s going to make a move.

1 · Reply

QuantNut Aug. 11 at 10:02 PM

$MBIO Enjoy the ride up til end of August shareholders. Its not gonna me massive but good enough 😉

2 · Reply

QuantNut Aug. 11 at 8:34 PM

$MBIO Now this one 👇 is the absolutely king of retards.

1 · Reply

QuantNut Aug. 11 at 8:31 PM

$MBIO Hmmm the dilutions huh? 845,385 = $84 6,394,261 = $600 You idiot really trying to scare people off with a less than $700 worth of dilution? lol. Got something better for you moron. Cash on hand (June 30, 2025): $12.66M Current quarterly burn: $1.36M They could operate into late 2027 without raising cash. Learn to read the Q10 you waffle merchant. And for those who are lazy to read the Q10, just run it through chatgpt and have it highlight the key takeaways. No need to listen to retards like 👇

0 · Reply

SEVENXStheGOAT Aug. 11 at 5:04 PM

$MBIO 😶‍🌫️😶‍🌫️ lets go

0 · Reply

krocks3 Aug. 11 at 5:00 PM

$MBIO

1 · Reply

Market Cap	10.93M
Revenue (ttm)	0.00
Net Income (ttm)	-15.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	109,300
Avg Vol	7,222,396
Day's Range	N/A - N/A
Shares Out	7.24M
Stochastic %K	12%
Beta	2.23
Analysts	Hold
Price Target	$8.00